Promising Phase 1 Results for Personalized Kidney Cancer Vaccine NeoVax
A phase 1 trial of NeoVax, a personalized cancer vaccine for kidney cancer, showed promising results in 9 patients, with all remaining disease-free after nearly three years; the vaccine induced a significant increase in T cells, highlighting its potential to prevent recurrence.
Promising Phase 1 Results for Personalized Kidney Cancer Vaccine NeoVax
A phase 1 trial of NeoVax, a personalized cancer vaccine for kidney cancer, showed promising results in 9 patients, with all remaining disease-free after nearly three years; the vaccine induced a significant increase in T cells, highlighting its potential to prevent recurrence.
Progress
40% Bias Score
Personalized Cancer Vaccine Shows Promise in Advanced Kidney Cancer
A small study of nine patients with advanced kidney cancer showed promising results using a personalized vaccine targeting neoantigens; after three years, all patients remained cancer-free, suggesting a new approach to treating this challenging disease.
Personalized Cancer Vaccine Shows Promise in Advanced Kidney Cancer
A small study of nine patients with advanced kidney cancer showed promising results using a personalized vaccine targeting neoantigens; after three years, all patients remained cancer-free, suggesting a new approach to treating this challenging disease.
Progress
44% Bias Score
Australian Father Races Against Time to Fund Emergency Kidney Cancer Surgery
A 57-year-old Australian father, Shakir Pichler, needs $\text{~}15,000 for an emergency kidney tumor removal surgery scheduled for December 18 due to a three-month wait in the public system; a GoFundMe campaign is underway.
Australian Father Races Against Time to Fund Emergency Kidney Cancer Surgery
A 57-year-old Australian father, Shakir Pichler, needs $\text{~}15,000 for an emergency kidney tumor removal surgery scheduled for December 18 due to a three-month wait in the public system; a GoFundMe campaign is underway.
Progress
48% Bias Score
Personalized Cancer Vaccine Shows Promise in Treating Advanced Kidney Cancer
A new personalized cancer vaccine shows promise in treating advanced kidney cancer; in a small study, nine patients with stage 3 or 4 kidney cancer remained cancer-free for an average of 34.7 months after receiving a vaccine tailored to their specific tumor type, triggering a significant immune resp...
Personalized Cancer Vaccine Shows Promise in Treating Advanced Kidney Cancer
A new personalized cancer vaccine shows promise in treating advanced kidney cancer; in a small study, nine patients with stage 3 or 4 kidney cancer remained cancer-free for an average of 34.7 months after receiving a vaccine tailored to their specific tumor type, triggering a significant immune resp...
Progress
40% Bias Score
Personalized Cancer Vaccine Shows Promising Results in Kidney Cancer Trial
A phase I trial at Dana-Farber Cancer Institute showed that a personalized cancer vaccine kept nine kidney cancer patients cancer-free for three years post-treatment; this is a significant advancement given the high recurrence rate of kidney cancer.
Personalized Cancer Vaccine Shows Promising Results in Kidney Cancer Trial
A phase I trial at Dana-Farber Cancer Institute showed that a personalized cancer vaccine kept nine kidney cancer patients cancer-free for three years post-treatment; this is a significant advancement given the high recurrence rate of kidney cancer.
Progress
40% Bias Score
Arsenic in US Drinking Water Linked to Increased Kidney Cancer Risk
A Texas A&M University study reveals a link between arsenic in drinking water and increased kidney cancer risk, affecting up to 40 million Americans, particularly those using private wells; even low FDA-approved arsenic levels show a 6% increased risk.
Arsenic in US Drinking Water Linked to Increased Kidney Cancer Risk
A Texas A&M University study reveals a link between arsenic in drinking water and increased kidney cancer risk, affecting up to 40 million Americans, particularly those using private wells; even low FDA-approved arsenic levels show a 6% increased risk.
Progress
40% Bias Score